Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI

Jun Feng Feng, Ken C. Van, Gene G Gurkoff, Christina Kopriva, Rafal T. Olszewski, Minsoo Song, Shifeng Sun, Man Xu, Joseph H. Neale, Po Wai Yuen, David A. Lowe, Jia Zhou, Bruce G Lyeth

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) leads to a rapid and excessive increase in glutamate concentration in the extracellular milieu, which is strongly associated with excitotoxicity and neuronal degeneration. N- acetylaspartylglutamate (NAAG), a prevalent peptide neurotransmitter in the vertebrate nervous system, is released along with glutamate and suppresses glutamate release by actions at pre-synaptic metabotropic glutamate autoreceptors. Extracellular NAAG is hydrolyzed to N-acetylaspartate and glutamate by peptidase activity. In the present study PGI-02776, a newly designed di-ester prodrug of the urea-based NAAG peptidase inhibitor ZJ-43, was tested for neuroprotective potential when administered intraperitoneally 30 min after lateral fluid percussion TBI in the rat. Stereological quantification of hippocampal CA2-3 degenerating neurons at 24 h post injury revealed that 10 mg/kg PGI-02776 significantly decreased the number of degenerating neurons (p < 0.05). Both average latency analysis of Morris water maze performance and assessment of 24-hour memory retention revealed significant differences between sham-TBI and TBI-saline. In contrast, no significant difference was found between sham-TBI and PGI-02776 treated groups in either analysis indicating an improvement in cognitive performance with PGI-02776 treatment. Histological analysis on day 16 post-injury revealed significant cell death in injured animals regardless of treatment. In vitro NAAG peptidase inhibition studies demonstrated that the parent compound (ZJ-43) exhibited potent inhibitory activity while the mono-ester (PGI-02749) and di-ester (PGI-02776) prodrug compounds exhibited moderate and weak levels of inhibitory activity, respectively. Pharmacokinetic assays in uninjured animals found that the di-ester (PGI-02776) crossed the blood-brain barrier. PGI-02776 was also readily hydrolyzed to both the mono-ester (PGI-02749) and the parent compound (ZJ-43) in both blood and brain. Overall, these findings suggest that post-injury treatment with the ZJ-43 prodrug PGI-02776 reduces both acute neuronal pathology and longer term cognitive deficits associated with TBI.

Original languageEnglish (US)
Pages (from-to)62-73
Number of pages12
JournalBrain Research
Volume1395
DOIs
StatePublished - Jun 13 2011

Fingerprint

Glutamate Carboxypeptidase II
Prodrugs
Protease Inhibitors
Wounds and Injuries
Glutamic Acid
Esters
Percussion
Neurons
Autoreceptors
Traumatic Brain Injury
PGI-02776
Blood-Brain Barrier
Nervous System
Neurotransmitter Agents
Vertebrates
Urea
Peptide Hydrolases
Cell Death
Pharmacokinetics
Pathology

Keywords

  • Glutamate
  • Hippocampus
  • Morris water maze
  • N-acetylaspartylglutamate (NAAG)
  • Traumatic brain injury (TBI)

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. / Feng, Jun Feng; Van, Ken C.; Gurkoff, Gene G; Kopriva, Christina; Olszewski, Rafal T.; Song, Minsoo; Sun, Shifeng; Xu, Man; Neale, Joseph H.; Yuen, Po Wai; Lowe, David A.; Zhou, Jia; Lyeth, Bruce G.

In: Brain Research, Vol. 1395, 13.06.2011, p. 62-73.

Research output: Contribution to journalArticle

Feng, JF, Van, KC, Gurkoff, GG, Kopriva, C, Olszewski, RT, Song, M, Sun, S, Xu, M, Neale, JH, Yuen, PW, Lowe, DA, Zhou, J & Lyeth, BG 2011, 'Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI', Brain Research, vol. 1395, pp. 62-73. https://doi.org/10.1016/j.brainres.2011.04.022
Feng, Jun Feng ; Van, Ken C. ; Gurkoff, Gene G ; Kopriva, Christina ; Olszewski, Rafal T. ; Song, Minsoo ; Sun, Shifeng ; Xu, Man ; Neale, Joseph H. ; Yuen, Po Wai ; Lowe, David A. ; Zhou, Jia ; Lyeth, Bruce G. / Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. In: Brain Research. 2011 ; Vol. 1395. pp. 62-73.
@article{6c18a1b564354d99811acf99a5d61d4a,
title = "Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI",
abstract = "Traumatic brain injury (TBI) leads to a rapid and excessive increase in glutamate concentration in the extracellular milieu, which is strongly associated with excitotoxicity and neuronal degeneration. N- acetylaspartylglutamate (NAAG), a prevalent peptide neurotransmitter in the vertebrate nervous system, is released along with glutamate and suppresses glutamate release by actions at pre-synaptic metabotropic glutamate autoreceptors. Extracellular NAAG is hydrolyzed to N-acetylaspartate and glutamate by peptidase activity. In the present study PGI-02776, a newly designed di-ester prodrug of the urea-based NAAG peptidase inhibitor ZJ-43, was tested for neuroprotective potential when administered intraperitoneally 30 min after lateral fluid percussion TBI in the rat. Stereological quantification of hippocampal CA2-3 degenerating neurons at 24 h post injury revealed that 10 mg/kg PGI-02776 significantly decreased the number of degenerating neurons (p < 0.05). Both average latency analysis of Morris water maze performance and assessment of 24-hour memory retention revealed significant differences between sham-TBI and TBI-saline. In contrast, no significant difference was found between sham-TBI and PGI-02776 treated groups in either analysis indicating an improvement in cognitive performance with PGI-02776 treatment. Histological analysis on day 16 post-injury revealed significant cell death in injured animals regardless of treatment. In vitro NAAG peptidase inhibition studies demonstrated that the parent compound (ZJ-43) exhibited potent inhibitory activity while the mono-ester (PGI-02749) and di-ester (PGI-02776) prodrug compounds exhibited moderate and weak levels of inhibitory activity, respectively. Pharmacokinetic assays in uninjured animals found that the di-ester (PGI-02776) crossed the blood-brain barrier. PGI-02776 was also readily hydrolyzed to both the mono-ester (PGI-02749) and the parent compound (ZJ-43) in both blood and brain. Overall, these findings suggest that post-injury treatment with the ZJ-43 prodrug PGI-02776 reduces both acute neuronal pathology and longer term cognitive deficits associated with TBI.",
keywords = "Glutamate, Hippocampus, Morris water maze, N-acetylaspartylglutamate (NAAG), Traumatic brain injury (TBI)",
author = "Feng, {Jun Feng} and Van, {Ken C.} and Gurkoff, {Gene G} and Christina Kopriva and Olszewski, {Rafal T.} and Minsoo Song and Shifeng Sun and Man Xu and Neale, {Joseph H.} and Yuen, {Po Wai} and Lowe, {David A.} and Jia Zhou and Lyeth, {Bruce G}",
year = "2011",
month = "6",
day = "13",
doi = "10.1016/j.brainres.2011.04.022",
language = "English (US)",
volume = "1395",
pages = "62--73",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI

AU - Feng, Jun Feng

AU - Van, Ken C.

AU - Gurkoff, Gene G

AU - Kopriva, Christina

AU - Olszewski, Rafal T.

AU - Song, Minsoo

AU - Sun, Shifeng

AU - Xu, Man

AU - Neale, Joseph H.

AU - Yuen, Po Wai

AU - Lowe, David A.

AU - Zhou, Jia

AU - Lyeth, Bruce G

PY - 2011/6/13

Y1 - 2011/6/13

N2 - Traumatic brain injury (TBI) leads to a rapid and excessive increase in glutamate concentration in the extracellular milieu, which is strongly associated with excitotoxicity and neuronal degeneration. N- acetylaspartylglutamate (NAAG), a prevalent peptide neurotransmitter in the vertebrate nervous system, is released along with glutamate and suppresses glutamate release by actions at pre-synaptic metabotropic glutamate autoreceptors. Extracellular NAAG is hydrolyzed to N-acetylaspartate and glutamate by peptidase activity. In the present study PGI-02776, a newly designed di-ester prodrug of the urea-based NAAG peptidase inhibitor ZJ-43, was tested for neuroprotective potential when administered intraperitoneally 30 min after lateral fluid percussion TBI in the rat. Stereological quantification of hippocampal CA2-3 degenerating neurons at 24 h post injury revealed that 10 mg/kg PGI-02776 significantly decreased the number of degenerating neurons (p < 0.05). Both average latency analysis of Morris water maze performance and assessment of 24-hour memory retention revealed significant differences between sham-TBI and TBI-saline. In contrast, no significant difference was found between sham-TBI and PGI-02776 treated groups in either analysis indicating an improvement in cognitive performance with PGI-02776 treatment. Histological analysis on day 16 post-injury revealed significant cell death in injured animals regardless of treatment. In vitro NAAG peptidase inhibition studies demonstrated that the parent compound (ZJ-43) exhibited potent inhibitory activity while the mono-ester (PGI-02749) and di-ester (PGI-02776) prodrug compounds exhibited moderate and weak levels of inhibitory activity, respectively. Pharmacokinetic assays in uninjured animals found that the di-ester (PGI-02776) crossed the blood-brain barrier. PGI-02776 was also readily hydrolyzed to both the mono-ester (PGI-02749) and the parent compound (ZJ-43) in both blood and brain. Overall, these findings suggest that post-injury treatment with the ZJ-43 prodrug PGI-02776 reduces both acute neuronal pathology and longer term cognitive deficits associated with TBI.

AB - Traumatic brain injury (TBI) leads to a rapid and excessive increase in glutamate concentration in the extracellular milieu, which is strongly associated with excitotoxicity and neuronal degeneration. N- acetylaspartylglutamate (NAAG), a prevalent peptide neurotransmitter in the vertebrate nervous system, is released along with glutamate and suppresses glutamate release by actions at pre-synaptic metabotropic glutamate autoreceptors. Extracellular NAAG is hydrolyzed to N-acetylaspartate and glutamate by peptidase activity. In the present study PGI-02776, a newly designed di-ester prodrug of the urea-based NAAG peptidase inhibitor ZJ-43, was tested for neuroprotective potential when administered intraperitoneally 30 min after lateral fluid percussion TBI in the rat. Stereological quantification of hippocampal CA2-3 degenerating neurons at 24 h post injury revealed that 10 mg/kg PGI-02776 significantly decreased the number of degenerating neurons (p < 0.05). Both average latency analysis of Morris water maze performance and assessment of 24-hour memory retention revealed significant differences between sham-TBI and TBI-saline. In contrast, no significant difference was found between sham-TBI and PGI-02776 treated groups in either analysis indicating an improvement in cognitive performance with PGI-02776 treatment. Histological analysis on day 16 post-injury revealed significant cell death in injured animals regardless of treatment. In vitro NAAG peptidase inhibition studies demonstrated that the parent compound (ZJ-43) exhibited potent inhibitory activity while the mono-ester (PGI-02749) and di-ester (PGI-02776) prodrug compounds exhibited moderate and weak levels of inhibitory activity, respectively. Pharmacokinetic assays in uninjured animals found that the di-ester (PGI-02776) crossed the blood-brain barrier. PGI-02776 was also readily hydrolyzed to both the mono-ester (PGI-02749) and the parent compound (ZJ-43) in both blood and brain. Overall, these findings suggest that post-injury treatment with the ZJ-43 prodrug PGI-02776 reduces both acute neuronal pathology and longer term cognitive deficits associated with TBI.

KW - Glutamate

KW - Hippocampus

KW - Morris water maze

KW - N-acetylaspartylglutamate (NAAG)

KW - Traumatic brain injury (TBI)

UR - http://www.scopus.com/inward/record.url?scp=79957926348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957926348&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2011.04.022

DO - 10.1016/j.brainres.2011.04.022

M3 - Article

C2 - 21565332

AN - SCOPUS:79957926348

VL - 1395

SP - 62

EP - 73

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -